Healthcare Analytical Testing Services Market Projected to Reach USD 12.46 Billion by 2030, Propelled by 10.8% CAGR

Nicole green

Nicole green

— 1 min read

Driven by the rising complexity of biologics and stringent global regulatory requirements, the global Healthcare Analytical Testing Services Market is set for a period of robust expansion. According to a new industry study, the market is valued at USD 7.48 billion in 2025 and is forecasted to reach USD 12.46 billion by 2030.

The surge in market value is primarily attributed to the increasing outsourcing of analytical capabilities by pharmaceutical, biopharmaceutical, and medical device companies. As these organizations strive for faster time-to-market and enhanced product quality, specialized testing partners have become essential for navigating the intricate landscape of method development, stability testing, and microbial analysis.

Key Market Highlights:

  • Genomic Growth: The genomic testing services segment is expected to register the highest growth rate, with a CAGR of 11.6%, fueled by the shift toward precision medicine.
  • Biopharma Dominance: Biopharmaceutical companies are projected to be the fastest-growing end-user segment (11.4% CAGR), reflecting the industry's massive investment in biosimilars and cell-based therapies.
  • Regional Leadership: North America remains the largest market, accounting for a 44.1% revenue share in 2024, supported by a high concentration of R&D facilities and strict FDA oversight.
  • Technological Integration: The adoption of AI-based analytics and digital platforms is revolutionizing data reliability and throughput across the product lifecycle.

The market is witnessing a transition from transactional testing to long-term strategic partnerships. These collaborations focus on "Quality by Design" (QbD) frameworks and continuous process verification. Furthermore, the integration of Laboratory Information Management Systems (LIMS) and AI-enabled image analytics is addressing the critical need for data integrity and faster interpretation of complex biological data.

Challenges and Opportunities

While the shortage of skilled analytical scientists and rising operational costs pose challenges, significant opportunities are emerging in decentralized testing models. Expanding biologics manufacturing in the Asia-Pacific region and the increasing focus on extractables and leachables testing for combination products continue to create new revenue streams for global service providers.

Read more